These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12482324)

  • 1. Role of conserved Asp293 of cytochrome P450 2C9 in substrate recognition and catalytic activity.
    Flanagan JU; McLaughlin LA; Paine MJ; Sutcliffe MJ; Roberts GC; Wolf CR
    Biochem J; 2003 Mar; 370(Pt 3):921-6. PubMed ID: 12482324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of arginine 97 and lysine 72 as determinants of substrate specificity in cytochrome P450 2C9 (CYP2C9).
    Davies C; Witham K; Scott JR; Pearson A; DeVoss JJ; Graham SE; Gillam EM
    Drug Metab Dispos; 2004 Apr; 32(4):431-6. PubMed ID: 15039296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants.
    Melet A; Marques-Soares C; Schoch GA; Macherey AC; Jaouen M; Dansette PM; Sari MA; Johnson EF; Mansuy D
    Biochemistry; 2004 Dec; 43(49):15379-92. PubMed ID: 15581350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential roles of Arg97, Asp293, and Arg108 in enzyme stability and substrate specificity of CYP2C9.
    Dickmann LJ; Locuson CW; Jones JP; Rettie AE
    Mol Pharmacol; 2004 Apr; 65(4):842-50. PubMed ID: 15044613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6.
    Paine MJ; McLaughlin LA; Flanagan JU; Kemp CA; Sutcliffe MJ; Roberts GC; Wolf CR
    J Biol Chem; 2003 Feb; 278(6):4021-7. PubMed ID: 12446689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors.
    Crewe HK; Barter ZE; Yeo KR; Rostami-Hodjegan A
    Biopharm Drug Dispos; 2011 Sep; 32(6):303-18. PubMed ID: 21725985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The substrate binding site of human liver cytochrome P450 2C9: an NMR study.
    Poli-Scaife S; Attias R; Dansette PM; Mansuy D
    Biochemistry; 1997 Oct; 36(42):12672-82. PubMed ID: 9335524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function.
    Ridderström M; Masimirembwa C; Trump-Kallmeyer S; Ahlefelt M; Otter C; Andersson TB
    Biochem Biophys Res Commun; 2000 Apr; 270(3):983-7. PubMed ID: 10772937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite.
    Flanagan JU; Maréchal JD; Ward R; Kemp CA; McLaughlin LA; Sutcliffe MJ; Roberts GC; Paine MJ; Wolf CR
    Biochem J; 2004 Jun; 380(Pt 2):353-60. PubMed ID: 14992686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of incorporating the 2C5 crystal structure into comparative models of cytochrome P450 2D6.
    Kirton SB; Kemp CA; Tomkinson NP; St-Gallay S; Sutcliffe MJ
    Proteins; 2002 Nov; 49(2):216-31. PubMed ID: 12211002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of aspartate-133 and histidine-458 in the mechanism of tryptophan indole-lyase from Proteus vulgaris.
    Demidkina TV; Zakomirdina LN; Kulikova VV; Dementieva IS; Faleev NG; Ronda L; Mozzarelli A; Gollnick PD; Phillips RS
    Biochemistry; 2003 Sep; 42(38):11161-9. PubMed ID: 14503866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the human CYP2C9*13 variant activity reduction: a molecular dynamics simulation and docking study.
    Zhou YH; Zheng QC; Li ZS; Zhang Y; Sun M; Sun CC; Si D; Cai L; Guo Y; Zhou H
    Biochimie; 2006 Oct; 88(10):1457-65. PubMed ID: 16740353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13.
    Guo Y; Wang Y; Si D; Fawcett PJ; Zhong D; Zhou H
    Xenobiotica; 2005 Sep; 35(9):853-61. PubMed ID: 16308280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of phenylalanine 120 on cytochrome P450 2D6 catalytic selectivity and regiospecificity: crucial role in 7-methoxy-4-(aminomethyl)-coumarin metabolism.
    Keizers PH; Lussenburg BM; de Graaf C; Mentink LM; Vermeulen NP; Commandeur JN
    Biochem Pharmacol; 2004 Dec; 68(11):2263-71. PubMed ID: 15498516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of phenylalanine 483 in cytochrome P450 2D6 is strongly substrate dependent.
    Lussenburg BM; Keizers PH; de Graaf C; Hidestrand M; Ingelman-Sundberg M; Vermeulen NP; Commandeur JN
    Biochem Pharmacol; 2005 Oct; 70(8):1253-61. PubMed ID: 16135359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid.
    Melet A; Assrir N; Jean P; Pilar Lopez-Garcia M; Marques-Soares C; Jaouen M; Dansette PM; Sari MA; Mansuy D
    Arch Biochem Biophys; 2003 Jan; 409(1):80-91. PubMed ID: 12464247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression, purification, and biochemical characterization of a human cytochrome P450 CYP2D6-NADPH cytochrome P450 reductase fusion protein.
    Deeni YY; Paine MJ; Ayrton AD; Clarke SE; Chenery R; Wolf CR
    Arch Biochem Biophys; 2001 Dec; 396(1):16-24. PubMed ID: 11716457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.
    Pilotto A; Seripa D; Franceschi M; Scarcelli C; Colaizzo D; Grandone E; Niro V; Andriulli A; Leandro G; Di Mario F; Dallapiccola B
    Gastroenterology; 2007 Aug; 133(2):465-71. PubMed ID: 17681167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of the decrease in catalytic activity of human cytochrome P450 2C9 polymorphic variants investigated by computational analysis.
    Sano E; Li W; Yuki H; Liu X; Furihata T; Kobayashi K; Chiba K; Neya S; Hoshino T
    J Comput Chem; 2010 Nov; 31(15):2746-58. PubMed ID: 20839301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative binding models for CYP2C9 based on benzbromarone analogues.
    Locuson CW; Rock DA; Jones JP
    Biochemistry; 2004 Jun; 43(22):6948-58. PubMed ID: 15170332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.